Genetic Testing in South Africa

By Crystal Lubbe

February 13, 2025

Could genetic testing be the key to preventing sudden cardiac deaths in South Africa? The recent study investigated the use of genetic testing in South Africa, specifically through next-generation sequencing (NGS), to identify genetic causes of sudden unexpected deaths (SUD) in a young South African cohort. It analysed DNA from 51 SUD cases, focusing on 49 genes linked to inherited cardiac arrhythmogenic disorders. The findings revealed that approximately 4% of the deaths were likely due to genetic arrhythmic or cardiac conduction disorders. This study highlights the importance of genetic testing in understanding and preventing sudden cardiac deaths in South Africa.

Key Insights into Genetic Testing

The study identified 175 different missense variants, with 92.5% being known and documented, and 7.4% being novel. Most variants were of benign or likely benign significance, while a small percentage were pathogenic or of unknown significance. Post-mortem genetic testing revealed that about 4% (2/51) of the SUD cases had a genetic arrhythmic or cardiac conduction disorder as the probable cause of death. The study emphasises the need for better detection, treatment, and prevention of sudden cardiac deaths in South Africa, especially in light of the significant increase in noncommunicable diseases, particularly cardiovascular diseases. Utilising NGS and the Galaxy bioinformatic platform for variant annotation and interpretation demonstrates the potential of advanced genetic testing to elucidate the causes of sudden unexpected deaths.

Public Health Concerns Globally

Sudden cardiac death is a major public health concern globally. In sub-Saharan Africa, including South Africa, it accounts for an estimated 50% of all cardiovascular deaths. Unfortunately, there is a lack of reliable statistics on its incidence in these regions.
Previous studies have shown the value of genetic testing in determining the underlying causes of sudden unexpected deaths, especially in cases where traditional post-mortem investigations are inconclusive. Research indicates that sudden deaths are more common among males, particularly in the 40-49 age group, and often result from cardiovascular and respiratory incidents. Genetic factors are identified in a small percentage of these cases.

The Transformative Role of Genetic Testing in South Africa: Implications for Health and Society

The integration of next-generation sequencing (NGS) into the investigation of sudden unexpected deaths in South Africa could have profound economic implications. By reducing the need for repeated and costly diagnostic procedures, early identification of genetic causes can lead to targeted preventive measures and treatment strategies, potentially lowering healthcare costs over time. From a public health perspective, the insights gained from genetic testing can significantly inform strategies aimed at preventing sudden cardiac deaths. By identifying genetic predispositions, public health programs can focus on genetic screening and counseling, ultimately leading to improved health outcomes and reduced mortality rates.

For families affected by sudden unexpected deaths, genetic testing offers the possibility of closure by providing a clearer understanding of the cause of death. It also has important genetic implications for family members, enabling early intervention and preventive measures that can safeguard their health. Moreover, the study emphasises the necessity for more comprehensive epidemiological data on sudden cardiac deaths in South Africa. Such data is crucial for policymakers to develop and implement effective health strategies and interventions, addressing the growing burden of cardiovascular diseases.

In conclusion, genetic testing in South Africa is an essential tool for uncovering the underlying genetic causes of sudden unexpected deaths. It not only enhances healthcare outcomes but also helps in devising strategies to mitigate associated risks, thereby playing a transformative role in the health and well-being of individuals and communities.

Reference url

Recent Posts

FDA Guidance on Overall Survival Assessment in Oncology Trials

By Staff Writer

August 20, 2025

Overall survival assessment serves as the gold standard for determining the true impact of oncology treatments, directly answering patient and provider questions such as: “How will this therapy affect my length of life?” According to the latest FDA guidance, robust overall survival assessment is ...
Guiding the Future of Digital Cardiac Rehabilitation: NICE’s Conditional Recommendations
The National Institute for Health and Care Excellence (NICE) has issued consultative draft guidance recommending six digital cardiac rehabilitation technologies for adults with cardiovascular disease (CVD). These technologies are conditionally recommended for use in the NHS during a three-year ev...
Assessment of Glofitamab With Gemcitabine in DLBCL Reveals No Additional Benefit

By João L. Carapinha

August 19, 2025

A recent G-BA decision provides a systematic evaluation of Glofitamab Gemcitabine DLBCL, combined with Gemcitabine and Oxaliplatin (GemOx), for treating adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplantation. The review...